dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Jul 18, 2013 20:38:03 GMT -5
Wedbush Securities Life Sciences
Management Access Conference
Stanley C. Erck
President and CEO
August 2012
Investment Highlights
• Recombinant vaccine company focused on innovative vaccines for
infectious disease with significant market opportunities
• Phase 2 vaccines for seasonal influenza and respiratory syncytial virus
(RSV) with recent positive data
‒ Two pandemic influenza trials in Phase 1
• Strong partnerships with BARDA and PATH provide substantial funding
and lower cash burn
‒ Corporate partnerships with Cadila (India) and LG (Korea)
• Virus-like particle (VLP) technology provides rapid, scalable, and
reliable vaccine production
• Strong balance sheet and biologics manufacturing infrastructure
• Multiple near-term catalysts for value creation
A LOT OF VERY INFORMATIVE INFO ON THE FOLLOWING LINK:
www.novavax.com/download/file/Novavax%20August%202012%20-%20SCE.pdf
|
|
